Plasma and urinary digoxin in thyroid dysfunction.
The response to a single oral dose of 0.5 mg digoxin has been studied in eight patients, of whom four were hyperthyroid and four were hypothyroid, both before and after treatment for their thyroid dysfunction. The post-dose plasma digoxin levels were significantly lower in the hyperthyroid patients when they were thyrotoxic than when they became euthyroid. In only one hypothyroid patient was the post-dose plasma digoxin level significantly higher before treatment than it was after and in the others the digoxin values reached were either the same as, or lower than, before treatment. There was a significant correlation between the creatinine clearance and the urinary concentrations of digoxin and these both altered with change in thyroid status. Total urinary digoxin excretion did not change. Pharmacokinetic analysis suggested that digoxin was distributed in a way compatible with a two-compartment model and that the volume of the central compartment was high in thyrotoxic patients and low in hypothyroid patients. In both cases it reverted to a median value after treatment. It is recommended that plasma digoxin levels should be monitored in all patients with thyroid dysfunction who require therapeutic digoxin.
D000368:Aged; D004077:Digoxin / Q000097:blood / Q000378:metabolism* / Q000652:urine; D005260:Female; D006801:Humans; D006980:Hyperthyroidism / Q000188:drug therapy / Q000378:metabolism* / Q000532:radiotherapy; D007037:Hypothyroidism / Q000188:drug therapy / Q000378:metabolism*; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D008875:Middle Aged; D008954:Models, Biological
D007457:Iodine Radioisotopes; D004077:Digoxin